BSIM Therapeutics is a biotech company focused on rational design of innovative therapeutic drugs for rare amyloid diseases. First products stand out as a new generation of transthyretin (TTR) stabilizers, designed to target multiple TTR variants in different tissues and organs severely affected in hereditary transthyretin amyloidoses (hATTR).

One pager 

Website: http://www.bsimsquare.com/